| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2009;120:851-858.)
© 2009 American Heart Association, Inc.
Coronary Heart Disease |
From the Department of Medicine (K.S., T.J.), Section of Cardiology, Huddinge, Karolinska Institute, Karolinska University Hospital, Stockholm; Division of Cardiovascular Medicine (P.L.), Division of Nephrology (S.H.J.), Department of Clinical Sciences, Karolinska Institute, Danderyd Hospital; Department of Internal Medicine (S.S.), Ryhov County Hospital, Jönköping; Uppsala Clinical Research Centre (J.L., L.W.), University Hospital, Uppsala; and Department of Cardiology (U.S.), University Hospital, Linköping; all in Sweden.
Correspondence to Karolina Szummer, Department of Cardiology, Karolinska University Hospital, Huddinge, Institution of Medicine (H7), Huddinge, Karolinska Institutet, 141 86 Stockholm, Sweden. E-mail karolina.szummer{at}karolinska.se
Received November 24, 2008; accepted June 15, 2009.
Background— It is unknown whether patients with non-ST-elevation myocardial infarction derive a similar benefit from an early invasive therapy at different levels of renal function.
Methods and Results— A total of 23 262 consecutive non-ST-elevation myocardial infarction patients
80 years old were included in a nationwide coronary care unit register between 2003 and 2006. Glomerular filtration rate (eGFR) was estimated with the Modification of Diet in Renal Disease Study formula. Patients were divided into medically or invasively treated groups if revascularized within 14 days of admission. A propensity score for the likelihood of invasive therapy was calculated. A Cox regression model with adjustment for propensity score and discharge medication was used to assess the association between early revascularization and 1-year mortality across renal function stages. There was a gradient, with significantly fewer patients treated invasively with declining renal function: eGFR
90 mL · min–1 · 1.73 m–2, 62%; eGFR 60 to 89 mL · min–1 · 1.73 m–2, 55%; eGFR 30 to 59 mL · min–1 · 1.73 m–2, 36%; eGFR 15 to 29 mL · min–1 · 1.73 m–2, 14%; and eGFR <15 mL · min–1 · 1.73 m–2/dialysis, 15% (P<0.001). After adjustment, the overall 1-year mortality was 36% lower (hazard ratio 0.64, 95% confidence interval 0.56 to 0.73, P<0.001) with an invasive strategy. The magnitude of survival difference was similar in normal-to-moderate renal function groups. The lower mortality observed with invasive therapy declined with lower renal function, with no difference in mortality in patients with kidney failure (eGFR <15 mL · min–1 · 1.73 m–2) or in those receiving dialysis (hazard ratio 1.61, 95% confidence interval 0.84 to 3.09, P=0.15).
Conclusions— Early invasive therapy is associated with greater 1-year survival in patients with non-ST-elevation myocardial infarction and mild-to-moderate renal insufficiency, but the benefit declines with lower renal function, and is less certain in those with renal failure or on dialysis.
Related Articles:
This article has been cited by other articles:
![]() |
C. P. Cannon Should We Manage Patients With Non-ST Segment Elevation Myocardial Infarction With Renal Failure With an Invasive Strategy? Circulation, September 8, 2009; 120(10): 828 - 830. [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2009 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |